Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25550757 | 0.95 | HSD17B1 (0.32) | PRKDCCA12CA1CA2CA9 | |
| SCHEMBL25550618 | 0.95 | PRKDC (0.37) | PRKDCCA12CA1CA2CA9 | |
| SCHEMBL25550601 | 0.95 | PRKDC (0.37) | PRKDCCA12CA1CA2CA9 | |
| SCHEMBL25550596 | 0.94 | CA12 (0.37) | PRKDCCA12CA1CA2CA9 | |
| SCHEMBL25550616 | 0.94 | PRKDC (0.35) | PRKDCCA12CA1CA2CA9 | |
| SCHEMBL25550730 | 0.93 | PRKDC (0.39) | PRKDCHSD17B1HSD17B2ALDH1A1MAPT | |
| SCHEMBL25551306 | 0.93 | PRKDC (0.39) | PRKDCHSD17B1HSD17B2ALDH1A1MAPT | |
| SCHEMBL25550614 | 0.92 | PRKDC (0.35) | PRKDCCA12CA1CA2CA9 | |
| SCHEMBL25550751 | 0.89 | PRKDC (0.34) | PRKDCCA12CA1CA2CA9 | |
| SCHEMBL25550607 | 0.89 | CA12 (0.36) | PRKDCCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172059-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
| US-20230172059-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172059-A1 | LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME | ESR1, NFE2L2, LAGE3 | PRKDC 3964/4885CA12 1319/4885CA1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.